Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSOTM (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Dec 14, 2018
Copyright Nasdaq. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.
Events & Presentations
Nov 28, 2018 at 9:30 AM EST
Piper Jaffray 30th Annual Healthcare Conference
Nov 14, 2018 at 9:30 AM EST
Stifel 2018 Healthcare Conference
Nov 6, 2018 at 8:00 AM EST
Sage Therapeutics Q3 2018 Financial Results Conference Call